12:30 – 13:15

Registration, networking and refreshments

13:15 – 14:30

Session 1:
The fast lane from innovation to proof of concept

From No to Yes: What are licensing partners looking for?

Dr. Olaf Ritzeler, Director, Rare Diseases External Innovation, Global Business Development & Licensing, Sanofi

The fast lane to proof of concept

Dr. Matthias Grossmann, VP, Parexel Early Phase Scientific Affairs

Clinical development strategies: Lessons learnt and implications for the future

Dr. Andrew Galazka, MD, Senior VP, Head of Global Medical Excellence at Merck

Current challenges in oncology development

Dr. Jens Wuerthner, Head of Clinical Development, ADC Therapeutics

Targeting the apoptosis pathways in cancer therapy:
POC and lessons from the development of Debio 1143

Grégoire Vuagniaux, Director, Translational Pharmacology & Screening Debiopharm Intl.

14:30 – 15:15

Break

15:15 – 16:15

Session 2:
New drug development technologies

Using biomarkers to improve the quality of decision making in drug development

Dr. Justin Devine, Chief Medical Officer, Synexa Group Life Sciences

Maximizing the value for emerging Biopharma companies

Claudia Graeve, VP Health Advances

Adaptive designs: Statistical, operational and regulatory issues

Pantelis Vlachos, Principal Strategic Consultant, Cytel Inc

16:15 – 16:45

Break

16:45 – 17:45

Session 3:
New frontiers in life science research & development

Healthcare future: Disruptive therapy innovation  

Philippe Menu, McKinsey & Company

IPO on SIX: The leadership team also goes public

Christian Fehr, Relationship Manager Primary Markets

When a trial has an unexpected outcome: Ways to protect yourself in a fast changing regulatory environment

Alex Forrest, Head of Life Sciences, Overseas Group, CHUBB Insurance

The China opportunity: Considerations for clinical strategy

Dr. Victor Cheng, Vice President, Technical, Parexel Consulting

17:45 – 18:45

Cocktail

Paternot room
Agora Cancer Research Centre, CHUV
Rue du Bugnon 25A
1005 Lausanne

Metro
Lausanne Metro M2, direction “Croisette”, stop: “CHUV” (1 min. walking distance)

Parking
CHUV Parking, Avenue de Beaumont 25, 1012 Lausanne (3 min. walking distance)

The Swiss Biotech Association is launching the Swiss biotech Insight event series, designed to cover a portfolio of topics mirroring the biopharma product life cycle, namely from ideation and research to commercialization and patient benefit. The three main areas covered are discovery, development and commercialization.

At the first event of the Insight series, we join forces with Parexel to address major clinical trial strategy challenges, including the growing complexity of trials, changing regulations, spiraling costs, and patient access. The meeting will explore the impact of real world data science, adaptive clinical trial design, biomarkers and more.

Please note that we may keep your personal details for the purpose of contacting you in the future on topics related to the Swiss Biotech Association. Photos, audio and video recordings take place at the event to support public communication activities.

By submitting the registering form, you agree to this use of your personal data and pictures.